Vertex Pharmaceuticals (VRTX) TD Cowen 46th Annual Health Care Conference summary

Company overview and strategic vision

• Leadership in cystic fibrosis (CF) continues, with expansion into heme, pain, and emerging renal verticals.

• Five programs are in pivotal development, with a robust phase II pipeline and strong research momentum.

• Diversification strategy began in 2012–2015, focusing on diseases with high unmet need and validated targets.

• The company maintains a strong and growing balance sheet, supporting increased stock buybacks.

• Emphasis on both internal and external innovation, with a methodical, disease-first approach to R&D.

Renal franchise and pipeline updates

• Pove in IgAN is on track for interim phase III data and submission in the first half of the year, with breakthrough designation and rolling FDA review.

• Phase II RUBY-3 data showed up to 64% protein reduction at 48 weeks; phase III RAINIER is placebo-controlled with similar design.

• Key efficacy markers include proteinuria reduction and GFR slope, aiming to delay death, dialysis, and transplantation.

• Safety focus is on infection risk due to B cell suppression, with phase II data supporting a favorable benefit/risk profile.

• Pove offers once-monthly, low-volume, auto-injector dosing, and potential for multiple renal indications.

AMKD and additional renal programs

• Inaxaplin phase III for APOL1-mediated kidney disease (AMKD) is fully enrolled for interim analysis, with results expected late this year or early next.

• Phase II inaxaplin data showed a 47.6% protein reduction; the program uses genetic inclusion and adaptive design.

• AMPLITUDE and AMPLIFIED studies address pure AMKD and AMKD with comorbidities, with next steps dependent on upcoming results.